Ching-Fei Li | Cancer therapy | Innovative Research Award

Posted on by Skincare

Innovative Research Award

Ching-Fei Li — The University of Texas MD Anderson Cancer Center, United States

Ching-Fei Li
Affiliation The University of Texas MD Anderson Cancer Center
Country United States
Scopus ID 57221912256
Documents 8
Citations 650
h-index 4
Subject Area Cancer therapy
Event World Skincare Innovation Awards
ORCID 0000-0001-7844-7003

Ching-Fei Li is a researcher affiliated with The University of Texas MD Anderson Cancer Center whose documented research activity includes molecular mechanisms of cancer progression, tumor biology, and therapeutic strategies. Publicly available research records associate Li with studies involving pancreatic cancer, cancer immunotherapy, lymphoma, and molecular regulation relevant to therapeutic response. [1] [2]

Abstract

Ching-Fei Li’s research profile is centered on cancer biology and therapeutic investigation. Available scholarly records document contributions to research concerning tumor progression, immune regulation, therapeutic resistance, and molecular targets for cancer treatment. The record includes work on pancreatic cancer and cancer immunotherapy, including research examining ADAR1 regulation and the interaction of therapeutic mechanisms with antitumor immune responses. [1] [3]

Keywords

Cancer therapy, cancer biology, cancer immunotherapy, pancreatic cancer, tumor microenvironment, therapeutic resistance, molecular oncology, ADAR1, immune regulation, lymphoma, translational cancer research.

Introduction

Cancer therapy research encompasses the identification of molecular mechanisms that regulate tumor growth, immune evasion, therapeutic response, and disease progression. Within this field, molecular oncology studies seek to connect mechanistic discoveries with potential therapeutic strategies. Public research records identify Ching-Fei Li with work in this broad area at The University of Texas MD Anderson Cancer Center. [2]

Research Profile

The supplied research profile identifies Ching-Fei Li with The University of Texas MD Anderson Cancer Center, United States, and lists cancer therapy as the principal subject area. The supplied bibliometric information records 8 documents, 650 citations, and an h-index of 4. These values should be understood as profile-specific bibliometric data supplied for this recognition page and may change as indexing databases are updated. [4]

Research Contributions

Li’s documented research contributions include studies of molecular pathways relevant to cancer progression and therapeutic intervention. One research direction concerns pancreatic cancer and mechanisms that may influence the response of tumors to immunotherapy. In a 2026 study, Li and collaborators investigated ADAR1 protein regulation and reported that all-trans retinoic acid promotes ADAR1 degradation through a mechanism involving USP7 and retinoylation, with implications for combination treatment involving immune checkpoint blockade. [3]

Publications

The supplied profile information records 8 documents associated with Scopus Author ID 57221912256. The input data identifies the researcher’s subject area as Cancer therapy and provides bibliometric information including 650 citations and an h-index of 4; however, specific publication titles, journals, publication years, complete author lists, and DOI identifiers were not supplied as profile fields. Accordingly, individual publications are not reproduced here to avoid attributing unsupported bibliographic details to the researcher. [4]

Research Impact

The available bibliometric information supplied for this page records 650 citations across 8 documents and an h-index of 4. These figures provide one quantitative description of the research record but should be interpreted in the context of database coverage, publication date, field-specific citation practices, and the changing nature of citation counts. [3]

Award Suitability

For an Innovative Research Award assessment, the documented profile provides several research dimensions that can be considered: cancer therapy, molecular oncology, cancer immunotherapy, pancreatic cancer biology, therapeutic resistance, and investigation of molecular mechanisms relevant to treatment. These areas are represented in the published research record and can be evaluated against the specific eligibility and assessment criteria established by the World Skincare Innovation Awards. [3]

Conclusion

Ching-Fei Li’s documented scholarly profile is associated with cancer therapy and molecular oncology at The University of Texas MD Anderson Cancer Center. The available record includes research concerning cancer immunotherapy, tumor biology, pancreatic cancer, immune regulation, and molecular mechanisms that may influence therapeutic response. [2] [3]

References

  1. Elsevier. (n.d.). Scopus author details: Ching-Fei Li, Author ID 57221912256. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57221912256
  2. Li, C.-F. et al. (2026). All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Nature Communications, 17, 6297.DOI:
    https://doi.org/10.1038/s41467-026-72271-5
  3. ORCID. Ching-Fei Li — ORCID record 0000-0001-7844-7003.
    https://orcid.org/0000-0001-7844-7003
  4. Fu, J. et al. (2024). Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Nature Communications.
    https://doi.org/10.1038/s41467-024-47242-3

Przemyslaw Zdziarski | Oncocytic Cancer | Best Researcher Award

Posted on by Skincare

Best Researcher Award

Przemyslaw Zdziarski – Wroclaw Medical University

Przemyslaw Zdziarski
Affiliation Wroclaw Medical University
Country Poland
Scopus ID 56480593200
Documents 425
Citations 461
h-index 10
Subject Area Oncocytic cancer
Event World Skincare Innovation Awards
ORCID View Profile

Przemyslaw Zdziarski is an academic researcher recognized for his interdisciplinary contributions to immunology and oncological studies. His work integrates clinical immunology, infectious disease research, and translational medicine approaches. He has contributed extensively to scientific literature with a focus on patient-centered outcomes. His recognition for the Best Researcher Award reflects both scholarly productivity and clinical relevance.[1]

Abstract

This article presents a structured overview of the academic contributions of Przemyslaw Zdziarski within the domain of immunology and oncocytic cancer research. It highlights his multidisciplinary research approach and clinical applications. The overview includes scholarly metrics and publication outputs. The recognition aligns with global academic evaluation standards.[2]

Keywords

The key areas of research include immunology, microbiome studies, infectious diseases, translational medicine, and oncocytic cancer. These keywords represent interdisciplinary connections. They highlight the integration of laboratory and clinical practices. The research emphasizes diagnostic and therapeutic innovation.[3]

Introduction

Academic recognition awards emphasize sustained scholarly contributions and innovation in research. Przemyslaw Zdziarski’s work exemplifies translational integration across clinical and experimental frameworks. His career spans multiple institutional collaborations and scientific domains. The award reflects measurable academic impact and consistent publication output.[1]

Research Profile

Zdziarski has an extensive academic background in infectious diseases and clinical immunology. His professional affiliations include major research institutes and clinical centers. His ORCID and Scopus profiles reflect a significant number of indexed publications. His work demonstrates a balance between theoretical research and applied clinical practice.[2]

Research Contributions

His research contributions focus on immunodeficiency disorders, cancer immunology, and microbiome analysis. He has explored interactions between infectious agents and immune responses. The studies often integrate case-based clinical evidence. His contributions advance understanding of disease mechanisms and therapeutic strategies.[3]

Publications

Zdziarski has authored numerous peer-reviewed articles in journals such as Biomedicines and Frontiers in Pharmacology. His publications address complex clinical scenarios including immune disorders and cancer-related complications. The works reflect methodological rigor and clinical relevance. His publication record supports academic recognition through measurable impact.[4]

Research Impact

The research impact is evidenced by citation metrics and collaborative studies across institutions. His work contributes to both academic discourse and clinical guidelines. The integration of patient-centered methodologies enhances real-world application. His citation profile indicates growing academic recognition.[2]

Award Suitability

The Best Researcher Award considers publication quality, research innovation, and academic impact. Zdziarski meets these criteria through consistent contributions and interdisciplinary approaches. His work aligns with global scientific standards. The award recognition supports continued advancement in medical research.[1]

Conclusion

In conclusion, Przemyslaw Zdziarski’s academic contributions represent a significant advancement in immunological and oncological research. His interdisciplinary focus enhances both theoretical and clinical outcomes. Recognition through academic awards reflects sustained scholarly excellence. Future research is expected to further extend his contributions.[4]

References

Hui Xiong | Pharmaceutics | Best Researcher Award

Posted on by Skincare

Dr. Hui Xiong | Pharmaceutics | Best Researcher Award
Associate Professor | China Pharmaceutical University | China

Dr. Hui Xiong is an Associate Professor in the Department of Pharmaceutics at China Pharmaceutical University, where she leads pioneering research in advanced drug delivery systems and nanomedicine engineering. She earned her Ph.D. in Pharmaceutics and has since focused her career on the rational design of multifunctional nanocarriers to improve the bioavailability, targeting precision, and therapeutic index of anticancer drugs. Her work integrates pharmaceutics, tumor biology, and materials science to develop innovative delivery platforms for combination therapy, pH-activated antiangiogenic chemotherapy, tumor microenvironment modulation, and ferroptosis-inducing therapeutic strategies, with a strong emphasis on breast and pancreatic cancer treatment. Dr. Xiong has published over 30 SCI papers as first or corresponding author in leading journals such as ACS Nano, Nano Letters, Journal of Controlled Release, Small, and Advanced Healthcare Materials, accumulating a total impact factor exceeding 188 and an H-index of 16. Her contributions include groundbreaking studies on vascular normalization, metabolic symbiosis-blocking nanocombinations, bioengineered nanospores for macrophage modulation, and redox-regulated nanodrugs, several of which have been featured on journal covers. She has been the principal investigator for multiple National Natural Science Foundation of China projects and holds four national invention patents, advancing translational pharmaceutics for clinical oncology. Recognized for her contributions to cancer nanomedicine, she also serves as a peer reviewer for several high-impact journals, further shaping the direction of pharmaceutics and targeted drug delivery research. 

Profile : ORCID

Publications

1. He, Z., Wang, R., Qi, Y., Liu, Y., Xiong, H.*, & Yao, J. (2024). Nanocoated bacteria with H₂S generation-triggered self-amplified photothermal and photodynamic effect for breast cancer therapy. Journal of Controlled Release.

2. Qiao, J., Liu, S., Huang, Y., Zhu, X., Xue, C., Wang, Y., Xiong, H.*, & Yao, J. (2024). Glycolysis–noncanonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment. Journal of Colloid and Interface Science.

3. Yao, L., Zhu, X., Shan, Y., Zhang, L., Yao, J., & Xiong, H.* (2024). Recent progress in anti-tumor nanodrugs based on tumor microenvironment redox regulation. Small.

4. Shang, Y., Lu, H., Liao, L., Li, S., Xiong, H.*, & Yao, J. (2023). Bioengineered nanospores selectively blocking LC3-associated phagocytosis in tumor-associated macrophages potentiate antitumor immunity. ACS Nano.

5. Xiong, H., Liu, X., Xie, Z., Zhu, L., Lu, H., Wang, C., & Yao, J. (2022). Metabolic symbiosis-blocking nanocombination for tumor vascular normalization treatment. Advanced Healthcare Materials.